Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis and consumer packaged goods
company, today announced that its medical cannabis division, Tilray
Medical, has released new medical cannabis products, under Tilray
and Aphria brands and launched
CannaPoints, a new
program designed to support patients through their medical cannabis
journey.
Blair MacNeil, President, Tilray Canada, said,
"We’re proud to expand our medical cannabis portfolio in Canada and
broaden our offerings for our growing patient community. Our new
CannaPoints program serves to guide our patients on their medical
cannabis journey and provide additional support as needed."
In Canada, Tilray Medical offers a broad
portfolio of medical cannabis brands including Tilray, Aphria,
Broken Coast, and Symbios. Understanding that patient needs are
unique, Tilray Medical’s latest release of high-quality medical
cannabis products from differentiated brands includes a
comprehensive range of THC and CBD products:
Tilray:
-
Tilray Sinaloa Gold: A high THC sativa strain.
Terpenes include d-Limonene, beta-Myrcene, and
beta-Caryophyllene.
-
Tilray Sapphire Scout: A genetic blend of Girl
Scout Cookies crossed with True OG. Terpenes include Limonene,
Linalool, and Trans-Caryophyllene.
-
Tilray Chem Cookies: Chem Cookies is a result of
two cannabis strains: Chemdawg #4 and Girl Scout Cookies (a.k.a.
GSC). Terpenes include d-Limonene, beta-Myrcene, and
beta-Caryophyllene.
-
Tilray Powdered Donuts #8: Powdered Donuts #8 is a
high-THC strain. Terpenes include d-Limonene, beta-Myrcene, and
beta-Caryophyllene.
Aphria:
-
Aphria Sherbet Cookies: Sherbet Cookies is a high
THC hybrid strain. Terpenes include Humulene, Nerolidol and
beta-Caryophyllene.
-
Aphria Banana Punch: Banana Punch is a high THC
hybrid strain made from Banana OG and Purple Punch. Terpenes
include limonene, pinene and beta-Caryophyllene.
-
Aphria Monkey Butter: Monkey Butter is another
high THC hybrid strain made from the combination of Gorilla Glue #4
x Peanut Butter Breath. Terpenes also include: Humulene, Cedrene,
and beta-Caryophyllene.
To further support the medical cannabis journey
for patients, Tilray Medical partnered with Strainprint, a mobile
app focused on medical cannabis tracking, to develop the
CannaPoints program. Alongside advice from a
physician, Tilray Medical patients can use the
CannaPoints program to explore new offerings,
learn more about strain details, and record the effects, making it
easier for them to curate optimal personal consumption schedules,
empowering them to tailor their own experiences and earn rewards
through the app in the process. Patients can download the app for
FREE, and kickstart their journey on the App Store, or Google Play
for Apple and Android devices.
About Tilray Medical Tilray
Medical is dedicated to transforming lives and fostering dignity
for patients in need through safe and reliable access to a global
portfolio of medical cannabis brands, including Tilray, Aphria,
Broken Coast, and Symbios. Tilray grew from being one of the first
companies to become an approved licensed producer of medical
cannabis in Canada to building the first GMP-certified cannabis
production facilities in Europe, first in Portugal and later in
Germany. Today, Tilray Medical is one of the biggest suppliers of
medical cannabis brands to patients, physicians, hospitals,
pharmacies, researchers, and governments, in 20 countries and
across five continents.
For more information on Tilray Medical, visit
Tilray Medical Canada and follow @TilrayMedical on Instagram.
About Tilray BrandsTilray
Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people’s lives for the better – one
person at a time – by inspiring and empowering the worldwide
community to live their very best life by providing them with
products that meet the needs of their mind, body, and soul and
invoke a sense of wellbeing. Tilray’s mission is to be the trusted
partner for its patients and consumers by providing them with a
cultivated experience of health and wellbeing through high-quality,
differentiated brands and innovative products. A pioneer in
cannabis research, cultivation, and distribution, Tilray’s
unprecedented production platform supports over 20 brands in over
20 countries, including comprehensive cannabis offerings,
hemp-based foods, and alcoholic beverages.
For more information on how we open a world of wellbeing,
visit www.Tilray.com and follow @Tilray on all social
platforms.
Forward-Looking
StatementsCertain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the Company’s ability
to commercialize new and innovative products worldwide. Many
factors could cause actual results, performance, or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Tilray and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC) of Tilray
made with the SEC and available on EDGAR. The forward-looking
statements included in this communication are made as of the date
of this communication and the Company does not undertake any
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events, or otherwise unless
required by applicable securities laws.
Contacts:
Tilray Global:Kaitlin
Macapagalnews@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.com
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024